TSHA
Taysha Gene Therapies, Inc. (TSHA) ESG Analysis Analysis (2026)
Overall Score
Environmental
No material environmental disclosure or sustainability-specific news was provided this month.
The company remains in a cash-intensive development phase, with negative free cash flow and high R&D spend (22.3% of revenue), which limits near-term environmental score improvement.
Social
No material social disclosure or workforce/customer news was provided this month.
High R&D intensity and a strong cash position support continued investment in talent and operations, but there is no fresh evidence of a step-change in social performance.
Governance
No material governance news, litigation, or capital-structure changes were provided this month.
Balance-sheet liquidity remains strong with a current ratio of 17.8x and cash ratio of 17.5x, but profitability and cash-flow metrics remain deeply negative.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Taysha Gene Therapies, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

